This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Watkins, H. Search for Related Content PubMed PubMed Citation Articles by Watkins, H. Related Collections Related Article

(Circulation. 2003;107:1344.)
© 2003 American Heart Association, Inc.

Editorial

Genetic Clues to Disease Pathways in Hypertrophic and Dilated Cardiomyopathies

Hugh Watkins, MD, PhD

From the University of Oxford, Oxford, UK.

Correspondence to Hugh Watkins, MD, PhD, Department of Cardiovascular Medicine, John Radcliffe Hospital, Oxford, OX2 8AF, UK. E-mail hugh.watkins@cardiov.ox.ac.uk

Key Words: Editorials • cardiomyopathy • genetics • myocardium • molecular biology

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Molecular genetic analysis of cardiomyopathies inherited as single-gene disorders is now a relatively mature field. Nevertheless, research in this area continues to throw up unexpected complexities that by challenging prevailing paradigms contribute important new insights into myocardial biology and disease processes.

See p 1390

Hypertrophic Cardiomyopathy: More Than a Disease of the Sarcomere?

A common finding in genetic analyses of an inherited condition is that a single clinical entity can be caused by mutations in multiple genes. Similarly, different mutations within a single gene can give rise to surprisingly diverse clinical conditions. Against this background, the genetic complexity that has been shown to underlie hypertrophic cardiomyopathy (HCM) is not unusual. Initially, the emerging picture appeared clear; namely, that HCM was a disease of the sarcomere, attributable to subtle perturbations (mostly missense mutations) affecting a number of components of the cardiac contractile apparatus.¹ As further candidate genes were tested, it became apparent that most, if not all, sarcomeric proteins could be mutated to cause HCM.^2,3 Although still fitting a single paradigm, these disease-genes encode proteins that contribute to cardiac contractility in very diverse ways — some enzymatic, some structural and others regulatory. Perhaps not surprisingly then, functional analyses have not shown a unifying abnormality of contractility as an explanation of the pathway to the HCM phenotype.⁴ Although the majority of HCM mutant contractile proteins lead to enhanced contractility, others seem to have the opposite effect by reducing maximum force output.^5–7 A proposal has been made that instead, the common abnormality is increased energy cost of force production,^4,5,8 and this has . . . [Full Text of this Article]

Related Article:

Mutations in the Human Muscle LIM Protein Gene in Families With Hypertrophic Cardiomyopathy

Christian Geier, Andreas Perrot, Cemil Özcelik, Priska Binner, Damian Counsell, Katrin Hoffmann, Bernhard Pilz, Yvonne Martiniak, Katja Gehmlich, Peter F.M. van der Ven, Dieter O. Fürst, Arnold Vornwald, Eberhard von Hodenberg, Peter Nürnberg, Thomas Scheffold, Rainer Dietz, and Karl Josef Osterziel
Circulation 2003 107: 1390-1395. [Abstract] [Full Text]

This article has been cited by other articles:

				C. Geier, K. Gehmlich, E. Ehler, S. Hassfeld, A. Perrot, K. Hayess, N. Cardim, K. Wenzel, B. Erdmann, F. Krackhardt, et al. Beyond the sarcomere: CSRP3 mutations cause hypertrophic cardiomyopathy Hum. Mol. Genet., September 15, 2008; 17(18): 2753 - 2765. [Abstract] [Full Text] [PDF]

				N. H. Robin, P. B. Tabereaux, R. Benza, and B. R. Korf Genetic Testing in Cardiovascular Disease J. Am. Coll. Cardiol., August 21, 2007; 50(8): 727 - 737. [Abstract] [Full Text] [PDF]

				P. Richard, E. Villard, P. Charron, and R. Isnard The Genetic Bases of Cardiomyopathies J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A79 - A89. [Abstract] [Full Text] [PDF]

				M. H. Yacoub Surgical Versus Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: The Pendulum Swings Circulation, July 26, 2005; 112(4): 450 - 452. [Full Text] [PDF]

				G. Thiene, D. Corrado, and C. Basso Cardiomyopathies: is it time for a molecular classification? Eur. Heart J., October 2, 2004; 25(20): 1772 - 1775. [Abstract] [Full Text] [PDF]

				L. Carrier, R. Knoll, N. Vignier, D. I Keller, P. Bausero, B. Prudhon, R. Isnard, M.-L. Ambroisine, M. Fiszman, J. Ross Jr., et al. Asymmetric septal hypertrophy in heterozygous cMyBP-C null mice Cardiovasc Res, August 1, 2004; 63(2): 293 - 304. [Abstract] [Full Text] [PDF]

				R. Ventura-Clapier, A. Garnier, and V. Veksler Energy metabolism in heart failure J. Physiol., February 15, 2004; 555(1): 1 - 13. [Abstract] [Full Text] [PDF]

				J. Flavigny, P. Robert, J.-C. Camelin, K. Schwartz, L. Carrier, and I. Berrebi-Bertrand Biomolecular interactions between human recombinant {beta}-MyHC and cMyBP-Cs implicated in familial hypertrophic cardiomyopathy Cardiovasc Res, November 1, 2003; 60(2): 388 - 396. [Abstract] [Full Text] [PDF]